Abstract: Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted/released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells.

Abstract: The present invention relates to synthetic DNA sequences which encode one or more collections of homologous proteins/(poly)peptides, and methods for generating and applying libraries of these DNA sequences. In particular, the invention relates to the preparation of a library of human-derived antibody genes by the use of synthetic consensus sequences which cover the structural repertoire of antibodies encoded in the human genome. Furthermore, the invention relates to the use of a single consensus antibody gene as a universal framework for highly diverse antibody libraries.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: An engine revolution limiter system is utilized to limit engine speed during a break-in period. The system provides for programming a variable break-in period and a variable selectable engine revolution limit. During the break-in period, if the revolution limit is exceeded by the engine speed, firing of the ignition is limited. In addition, the system provides for an over revolution limit wherein the ignition stops firing if the over revolution limit is exceeded. In addition, multiple break-in periods may be programmed with different associated revolution limits and over revolution limits. This provides for gradually increasing the allowable engine speed as the engine has been operating for greater periods of time.

Abstract: Block copolymers based on poly(ortho esters) containing amine groups. These block copolymers have both hydrophilic and hydrophobic blocks. They form micelles in aqueous solution, making them suitable for encapsulation or solubilization of hydrophobic or water-insoluble materials; and they also form bioerodible matrices for the sustained release of active agents.

Abstract: The present invention relates to a nonvolatile memory device, and more specifically, to a programmable nonvolatile logic switch memory (register) device using a resistive memory device. The programmable nonvolatile register uses a logic switch or a nonvolatile resistive memory device whose resistive state can be set by flowing a controlled current through it.

Abstract: Presented are methods and compositions for targeted chromosomal genomic alterations using modified single-stranded oligonucleotides. The oligonucleotides of the invention have at least one modified nuclease-resistant terminal region comprising phosphorothioate linkages, LNA analogs or 2?-O-Me base analogs.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: A diode pumped, multi axial mode, intracavity doubled, intracavity tripled laser, includes at least two resonator mirrors defining a resonator cavity. A laser crystal and a doubling crystal are positioned in the resonator cavity. A tripling crystal is also positioned in the resonator cavity. A diode pump source supplies a pump beam to the laser crystal and produces a laser crystal beam with a plurality of axial modes that are incident on the doubling crystal. This produces a frequency doubled output beam. Further, a diode pumped, multi axial mode, intracavity nonlinearly-converted laser is provided and includes at least two resonator mirrors defining a resonator cavity, a laser crystal and a nonlinear conversion apparatus positioned in the resonator cavity. A nonlinear conversion apparatus is also positioned in the resonator cavity.

Abstract: Compositions, methods, and devices are provided for inducing or enhancing the growth, proliferation, regeneration of inner ear tissue, particularly inner ear hair cells. In addition, provided are compositions and methods for prophylactic or therapeutic treatment of a mammal afflicted with an inner ear disorder or condition, particularly for hearing impairments involving hair cell damage, loss, or degeneration, by administration of a therapeutically effective amount of IGF-1 or FGF-2, or their agonists, alone or in combination.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The device for controlling a setup/hold time of an input signal can change a setup/hold time of various control signals applied from an input buffer without physically changing the control device. The device for controlling a setup/hold time of an input signal has transmission gates for performing selectively switching operations according to a decoded test mode control signal, thereby selectively using a signal delay device in driving of drivers to appropriately control the setup/hold time of various control signals applied from a global bus line. Accordingly, the device for controlling a setup/hold time of an input signal can provide a technique which can optimize the setup/hold time at a small cost in comparison with a physical metal option control system.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: An input buffer of a semiconductor memory device includes a first buffer block for buffering an input data through a delay path selected from a plurality of delay paths, and a second buffer block for buffering an input data strobe signal through a delay path selected from a plurality of delay paths, wherein the plurality of delay paths of the first buffer block and the plurality of delay paths of the second buffer block are identically formed by the same devices, and the corresponding delay paths are selected from the plurality of delay paths according to the same selecting signals. Although the input buffer fails to obtain a margin of a data setup and hold time in an input/output sense amplifier due to variations of the data setup and hold time by maximum and minimum values of tDQSS in a write operation mode, the input buffer can easily obtain the margin of the data setup and hold time in response to a special test mode signal.

Abstract: This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.

Abstract: The present invention provides a kit and a method for targeting of a diagnostic or therapeutic agent to a target site in a mammal having a pathological condition. The kit comprises, in separate containers, (a) a first conjugate comprising a targeting moiety and a Morpholino oligomer, wherein the targeting moiety selectively binds to a primary, target-specific binding site of the target site or to a substance produced by or associated with the target site; (b) optionally, a clearing agent; and (c) a second conjugate comprising a complementary Morpholino oligomer and a diagnostic agent or therapeutic agent. The method comprises administering (a), optionally (b), and (c) to a mammal.

Abstract: A chimeric phosphorylation indicator is provided. A chimeric phosphorylation indicator can contain a donor molecule, a phosphorylatable domain, a phosphoaminoacid binding domain (PAABD), and an acceptor molecule. A chimeric phosphorylation indicator also can contain a phosphorylatable polypeptide and a fluorescent protein, wherein the phosphorylatable polypeptide is contained within the sequence of the fluorescent protein, or wherein the fluorescent protein is contained within the sequence of the phosphorylatable polypeptide. Also provided are polynucleotides encoding such chimeric phosphorylation indicators, as well as kits containing the indicators or the polynucleotides. In addition, a method of using the chimeric phosphorylation indicators to detect a kinase or phosphatase in a sample is provided.

Abstract: Disclosed is a nonvolatile ferroelectric FeRAM control device which allows a programmable register to be stably driven in a low voltage region by controlling a pumping voltage supplied to the register. A pumping voltage controller is configured to output a pumping voltage control signal by receiving a power voltage control signal having a different output level according to a power voltage region where a power voltage belongs when the power control signal is applied. A cell plate voltage controller is configured to selectively output a cell plate pumping voltage control signal depending on states of the power voltage control signal, when a cell plate control signal is applied. A write enable voltage controller is configured to selectively output a write enable pumping voltage control signal depending on states of the power voltage control signal, when a write enable control signal is applied.